CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1997; 47:351
doi: 10.3322/canjclin.47.6.351
© 1997 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Skarin, A. T.
Right arrow Articles by Dorfman, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skarin, A. T.
Right arrow Articles by Dorfman, D. M.

CA: A Cancer Journal for Clinicians, Vol 47, Issue 6 351-372, Copyright © 1997 by American Cancer Society

ARTICLES

Non-Hodgkin's lymphomas: current classification and management

A. T. Skarin and D. M. Dorfman
Adult Oncology Department, Dana-Farber/Partners Cancer Care, Boston, MA, USA.

Considerable progress has been made in the classification of non-Hodgkin's lymphomas during the past 15 years, and the use of specific monoclonal antibodies directed against cell surface antigens has contributed to the understanding of the immunology of the disease. Early-stage indolent lymphoma is treated with radiotherapy; treatment of advanced-stage indolent lymphoma varies. Aggressive lymphomas are treated with combination chemotherapy with or without regional radiotherapy, and highly aggressive lymphomas are treated with regimens similar to those for children with leukemia.


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
S Bernatsky, R Ramsey-Goldman, R Rajan, J-F Boivin, L Joseph, S Lachance, D Cournoyer, A Zoma, S Manzi, E Ginzler, et al.
Non-Hodgkin's lymphoma in systemic lupus erythematosus
Ann Rheum Dis, October 1, 2005; 64(10): 1507 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Zhou, N. B. Levy, H. Xie, L. Qian, C.-Y. G. Lee, R. D. Gascoyne, and R. W. Craig
MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes
Blood, June 15, 2001; 97(12): 3902 - 3909.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. N. Mainwaring, D. Cunningham, W. Gregory, P. Hoskin, B. Hancock, A. J. Norton, K. MacLennan, P. Smith, G. V. Hudson, and D. Linch
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO
Blood, May 15, 2001; 97(10): 2991 - 2997.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. J. Dave, M. M. Hess, D. L. Pickering, D. H. Zaleski, A. L. Pfeifer, D. D. Weisenburger, J. O. Armitage, and W. G. Sanger
Rearrangements of Chromosome Band 1p36 in Non-Hodgkin's Lymphoma
Clin. Cancer Res., June 1, 1999; 5(6): 1401 - 1409.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by American Cancer Society.